Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

USAMRIID Reports Genetic Changes in Ebola Virus May Impede Potential Treatments

PHILADELPHIA, Jan. 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today that in a new publication in the journal mBio, scientists at...
January 15, 2015 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Awarded $770,852 by Federal Judge

WILMINGTON, Del., Jan. 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced that after prevailing in a federal lawsuit brought against the...
November 14, 2014 16:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reports on Annual Stockholder Meeting

PHILADELPHIA, Nov. 14, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE MKT:HEB) announced that it held its 2014 Annual Meeting of Stockholders on November 12, 2014. Final voting results will...
November 10, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Nine Months Ended September 30, 2014

PHILADELPHIA, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three and nine months ended September 30, 2014. The net loss (including non-cash...
November 03, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma and United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Collaborate on Alferon(R) and Ampligen(R) Against the Ebola Virus

PHILADELPHIA, Nov. 3, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has been informed by USAMRIID scientists that they have in-vitro data...
October 20, 2014 12:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola

PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government...
October 20, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Prevails in Multi-Million Dollar Federal Lawsuit

PHILADELPHIA, Oct. 20, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that a federal judge in Delaware has dismissed all claims...
September 29, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Expands Research on Potential Ebola Treatments to Five Independent Experts/Institutional Collaborators

PHILADELPHIA, Sept. 29, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a widened set of research collaborations designed to develop...
September 22, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Announces Primate Research Showing Alferon(R) LDO Protection From Pulmonary Damage Associated With Infection by Highly Pathogenic Influenza Virus

PHILADELPHIA, Sept. 22, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Protection from...
September 15, 2014 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx' Drug Ampligen Plus Intranasal Seasonal Influenza Vaccine Induces Cross-Reactive Antibody Formation Against Avian H5N1 and H7N9 Influenza HA in Humans

PHILADELPHIA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today a peer-reviewed publication entitled "Intranasal Seasonal...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right